Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

JAMA dermatology·2026
Same author

Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.

PloS one·2026
Same author

An opportunity to improve the quality of care for patients with chronic spontaneous urticaria: A reimagined 3-step real-world study protocol.

The journal of allergy and clinical immunology. Global·2026
Same author

Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.

American journal of clinical dermatology·2025
Same author

SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement.

The British journal of dermatology·2025
Same author

Biologic Sequence for the Treatment of Psoriatic Arthritis Following Nonresponse: A Narrative Review.

Dermatology and therapy·2025
Same journal

Transnasal Humidified Rapid-Insufflation Ventilatory Exchange versus Oropharyngeal Airway-Assisted Face-Mask Ventilation for Gastric Insufflation During Induction of General Anesthesia in Patients at High Risk for Obstructive Sleep Apnea.

Therapeutics and clinical risk management·2026
Same journal

Blood-Based Inflammatory and Metabolic Biomarkers for Assessing Symptom Burden and Quality of Life in Older Adults with Cancer: A Narrative Review.

Therapeutics and clinical risk management·2026
Same journal

The Future of Interventional Keratoconus Management: Perspectives on Integrating Epithelium-on Oxygen-Enriched Cross-Linking into Comprehensive Care Pathways.

Therapeutics and clinical risk management·2026
Same journal

Transcranial Magnetic Stimulation Combined with Speech-Language Therapy for Post-Stroke Aphasia Recovery: A Systematic Review and Network Meta-Analysis.

Therapeutics and clinical risk management·2026
Same journal

Risk Factors for Hypoglycemia in Type 2 Diabetes Mellitus Patients Using Once-Weekly Semaglutide: A Matched Case-Control Study.

Therapeutics and clinical risk management·2026
Same journal

Extracellular Vesicle-Based Strategies for the Prevention of Chemotherapy-Induced Cardiotoxicity.

Therapeutics and clinical risk management·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Treating psoriasis with adalimumab.

Eihab A Alwawi1, Stephanie L Mehlis, Kenneth B Gordon

  • 1Division of Dermatology and Department of Medicine, Evanston Northwestern Healthcare Skokie, IL, USA.

Therapeutics and Clinical Risk Management
|August 30, 2008
PubMed
Summary
This summary is machine-generated.

Adalimumab, a targeted biologic therapy, shows significant efficacy and good tolerability for treating moderate to severe chronic plaque psoriasis. This anti-tumor necrosis factor alpha (TNF) agent offers a promising new treatment option for psoriasis patients.

Keywords:
adalimumabpsoriasistumor necrosis factor alpha

More Related Videos

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Related Experiment Videos

Last Updated: Jul 2, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Area of Science:

  • Immunodermatology
  • Inflammatory skin diseases
  • Biologic therapies

Background:

  • Psoriasis is a chronic inflammatory skin condition impacting quality of life.
  • Advances in understanding psoriasis pathophysiology enable targeted therapies.
  • Biologic immunotherapies targeting tumor necrosis factor alpha (TNF) are effective treatments.

Purpose of the Study:

  • To evaluate the efficacy and safety of adalimumab, a new anti-TNF agent, for chronic plaque psoriasis.

Main Methods:

  • Review of recently released data from large, randomized clinical trials.
  • Assessment of adalimumab's performance in treating moderate to severe chronic plaque psoriasis.

Main Results:

  • Adalimumab demonstrated significant efficacy in treating chronic plaque psoriasis.
  • The new anti-TNF agent was found to be well tolerated by patients.

Conclusions:

  • Adalimumab is a promising therapeutic option for moderate to severe chronic plaque psoriasis.
  • This human monoclonal antibody represents a significant advancement in psoriasis treatment.